Attorney of Record

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

			STATEMEN	T UNDER 37 C	CFR 3	.73(b)	
Applicar	nt/Patent Ow	ner: MedImmune Lim	ited				
		nt No.: 09/706,507		File	d/Issu	e Date: November 3, 2000	
Titled:	Methods t	or Producing Member	s of Specific E	Binding Pairs			
MedImr	nune Limite	d	, a	Corporation			
(Name of	Assignee)			(Type of Assigne	e, e.g.,	corporation, partnership, university, government agency, etc.	
states th	nat it is:						
1. 🛚	the assig	nee of the entire right, til	le, and interest	in;			
2.		nee of less than the entirent (by percentage) of its			%	; or	
3.	the assig	nee of an undivided inte	rest in the entire	ety of (a complet	e assi	gnment from one of the joint inventors was made)	
the pate	ent application	n/patent identified above	, by virtue of eit	her:			
Α	the Unite	An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the United States Patent and Trademark Office at Reel, Frame, or for which a copy therefore is attached.					
OR .							
в. 🔀	,		i), of the patent	application/pate		ntified above, to the current assignee as follows: Cambridge Antibody Technology Limited	
	1. From						
		The document was rec Reel 008301				Trademark Office at, or for which a copy thereof is attached.	
	2. From	Cambridge Antiboo	ly Technology	Limited	To:	Cambridge Antibody Technology Limited	
		The document was rec	orded in the Un	ited States Pater	nt and	Trademark Office at	
		Reel 015139	, Fram	e 0506		_, or for which a copy thereof is attached.	
	3. From	Cambridge Antiboo	ly Technology	Limited	To:	MedImmune Limited	
		The document was rec	orded in the Un	ited States Pater	nt and	Trademark Office at	
		Reel 023379				_, or for which a copy thereof is attached.	
	Addition	al documents in the cha	in of title are list	ed on a supplem	nental	sheet(s).	
		y 37 CFR 3.73(b)(1)(i), y is being, submitted for				n of title from the original owner to the assignee was,	
						nent(s)) must be submitted to Assignment Division in the USPTO. <u>See</u> MPEP 302.08]	
The unc	dereigned (wh	noss titls is supplied beld	w) is authorize	d to act on behal	lf of th	e assignes.	
/David \	W. Clough/					December 3, 2011	
	Signature					Date	

This collection of information is required by 37 CFR 373(0). The information is required to obtain or retain a hernelf by the public which is to file (and by the LSFTO to process) an application. Confidentiality is governed by \$5 U.S.C. 122 and \$2 CFR 114 and 114. This collection is estimated to take it information to complete including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete the from aniotic suggestors for rectaing this burden, should be sent to the Cheff information Officer, U.S. Patient and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patients, P.O. Box 1450, Alexandria, VA 22313-1450.

David W. Clough

Printed or Typed Name

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 L. 95(2)(2)(2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether disclosure of these records is required by the Freedom of Information Act.
- A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing coursel in the course of settlement neodibations.
- A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record
- A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
- A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
- A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- 8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspection or an issued patent.
- A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or reculation.